Availability, affordability, access, and pricing of anti-cancer medicines in low-and middle-income countries: a systematic review of literature
Background: Cancer is the second leading cause of death globally accounting for more than
half of deaths in Low-and Middle-Income Countries (LMICs). Cancer treatment is expensive …
half of deaths in Low-and Middle-Income Countries (LMICs). Cancer treatment is expensive …
A systematic literature review of healthcare supply chain and implications of future research
Purpose This paper aims to review the healthcare supply chain (HSC) literature along
various areas and to find out the gap in it. Design/methodology/approach In total, 143 …
various areas and to find out the gap in it. Design/methodology/approach In total, 143 …
Quantifying the financial burden of households' out-of-pocket payments on medicines in India: a repeated cross-sectional analysis of National Sample Survey data …
S Selvaraj, HH Farooqui, A Karan - BMJ open, 2018 - bmjopen.bmj.com
Objective The objective of this research is to generate new evidence on financial
implications of medicines out-of-pocket (OOP) payments for households. Another objective …
implications of medicines out-of-pocket (OOP) payments for households. Another objective …
Community level antibiotic utilization in India and its comparison vis-à-vis European countries: evidence from pharmaceutical sales data
HH Farooqui, S Selvaraj, A Mehta, DL Heymann - PloS one, 2018 - journals.plos.org
India was the largest consumer of antibiotics in 2010 in the world. Evidence suggests that
countries with high per-capita antibiotic consumption have higher rates of antibiotic …
countries with high per-capita antibiotic consumption have higher rates of antibiotic …
The effects of medicines availability and stock-outs on household's utilization of healthcare services in Dodoma region, Tanzania
A Kuwawenaruwa, K Wyss… - Health policy and …, 2020 - academic.oup.com
Low-and middle-income countries have been undertaking health finance reforms to address
shortages of medicines. However, data are lacking on how medicine availability and stock …
shortages of medicines. However, data are lacking on how medicine availability and stock …
Cost of delivering health care services in public sector primary and community health centres in North India
Background With the commitment of the national government to provide universal
healthcare at cheap and affordable prices in India, public healthcare services are being …
healthcare at cheap and affordable prices in India, public healthcare services are being …
Cost of hemodialysis in a public sector tertiary hospital of India
Introduction Nearly 220000 patients are diagnosed with end-stage renal disease (ESRD)
every year, which calls for an additional demand of 34 million dialysis sessions in India. The …
every year, which calls for an additional demand of 34 million dialysis sessions in India. The …
Clinical management of type 2 diabetes in south Asia
A Misra, N Sattar, N Tandon, U Shrivastava… - The lancet Diabetes & …, 2018 - thelancet.com
Compared with other ethnic groups, south Asian people with type 2 diabetes tend to develop
the disease at a younger age and manifest with higher glycaemia, dyslipidaemia …
the disease at a younger age and manifest with higher glycaemia, dyslipidaemia …
Components of out-of-pocket expenditure and their relative contribution to economic burden of diseases in India
Importance High out-of-pocket expenditure (OOPE) on health in India may limit achieving
universal health coverage. A clear insight on the components of health expenditure may be …
universal health coverage. A clear insight on the components of health expenditure may be …
Real-world cost-effectiveness of pan-genotypic Sofosbuvir-Velpatasvir combination versus genotype dependent directly acting anti-viral drugs for treatment of hepatitis …
Background We undertook this study to assess the incremental cost per quality adjusted life
year (QALY) gained with the use of pan-genotypic sofosbuvir (SOF)+ velpatasvir (VEL) for …
year (QALY) gained with the use of pan-genotypic sofosbuvir (SOF)+ velpatasvir (VEL) for …